Bonus Biogroup - Asset Resilience Ratio

Latest as of March 2024: 10.04%

Bonus Biogroup (BONS) has an Asset Resilience Ratio of 10.04% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BONS working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

ILA3.90 Million
≈ $10.45K USD Cash + Short-term Investments

Total Assets

ILA38.85 Million
≈ $104.16K USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2008–2015)

This chart shows how Bonus Biogroup's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see BONS total assets.

Liquid Assets Composition Over Time

This chart breaks down Bonus Biogroup's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore BONS strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ILA0.00 0%
Short-term Investments ILA3.90 Million 10.04%
Total Liquid Assets ILA3.90 Million 10.04%

Asset Resilience Insights

  • Moderate Liquidity: Bonus Biogroup has 10.04% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Bonus Biogroup Industry Peers by Asset Resilience Ratio

Compare Bonus Biogroup's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
CSL Ltd
AU:CSL
Biotechnology 0.41%
Vaxcyte Inc
NASDAQ:PCVX
Biotechnology 41.54%
Bachem Holding AG
SW:BANB
Biotechnology 0.00%
Definium Therapeutics, Inc.
NASDAQ:DFTX
Biotechnology 38.51%
Chongqing Zhifei Bio Products
SHE:300122
Biotechnology -0.08%
HLB Co. Ltd
KQ:028300
Biotechnology 3.29%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
Biotechnology 0.12%

Annual Asset Resilience Ratio for Bonus Biogroup (2008–2015)

The table below shows the annual Asset Resilience Ratio data for Bonus Biogroup.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2015-12-31 1.88% ILA108.00K
≈ $289.54
ILA5.76 Million
≈ $15.43K
-20.23pp
2014-12-31 22.11% ILA1.00 Million
≈ $2.68K
ILA4.52 Million
≈ $12.13K
-42.61pp
2013-12-31 64.72% ILA5.28 Million
≈ $14.15K
ILA8.16 Million
≈ $21.87K
-12.06pp
2012-12-31 76.78% ILA6.80 Million
≈ $18.22K
ILA8.85 Million
≈ $23.73K
+71.44pp
2010-12-31 5.34% ILA324.00K
≈ $868.63
ILA6.07 Million
≈ $16.28K
+0.43pp
2009-12-31 4.90% ILA2.42 Million
≈ $6.49K
ILA49.39 Million
≈ $132.40K
+0.78pp
2008-12-31 4.13% ILA2.10 Million
≈ $5.62K
ILA50.81 Million
≈ $136.21K
--
pp = percentage points

About Bonus Biogroup

TA:BONS Israel Biotechnology
Market Cap
$62.31 Million
ILA23.24 Billion ILA
Market Cap Rank
#21128 Global
#278 in Israel
Share Price
ILA19.90
Change (1 day)
+13.07%
52-Week Range
ILA17.20 - ILA58.50
All Time High
ILA171.00
About

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of… Read more